These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 12134023

  • 1. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.
    Keating S, Prince S, Jones M, Rowe M.
    J Virol; 2002 Aug; 76(16):8179-88. PubMed ID: 12134023
    [Abstract] [Full Text] [Related]

  • 2. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.
    Quinn LL, Williams LR, White C, Forrest C, Zuo J, Rowe M.
    J Virol; 2016 Jan 01; 90(1):356-67. PubMed ID: 26468525
    [Abstract] [Full Text] [Related]

  • 3. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
    Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD.
    PLoS Pathog; 2009 Jun 01; 5(6):e1000490. PubMed ID: 19557156
    [Abstract] [Full Text] [Related]

  • 4. Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2.
    Zuo J, Thomas WA, Haigh TA, Fitzsimmons L, Long HM, Hislop AD, Taylor GS, Rowe M.
    PLoS Pathog; 2011 Dec 01; 7(12):e1002455. PubMed ID: 22216005
    [Abstract] [Full Text] [Related]

  • 5. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.
    Ressing ME, Keating SE, van Leeuwen D, Koppers-Lalic D, Pappworth IY, Wiertz EJ, Rowe M.
    J Immunol; 2005 Jun 01; 174(11):6829-38. PubMed ID: 15905524
    [Abstract] [Full Text] [Related]

  • 6. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation.
    Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, Ressing ME, Wiertz EJ, Rowe M.
    PLoS Pathog; 2009 Jan 01; 5(1):e1000255. PubMed ID: 19119421
    [Abstract] [Full Text] [Related]

  • 7. The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing.
    Pappworth IY, Wang EC, Rowe M.
    J Virol; 2007 Jan 01; 81(2):474-82. PubMed ID: 17079298
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
    Lear AL, Rowe M, Kurilla MG, Lee S, Henderson S, Kieff E, Rickinson AB.
    J Virol; 1992 Dec 01; 66(12):7461-8. PubMed ID: 1331531
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication.
    Guerreiro-Cacais AO, Uzunel M, Levitskaya J, Levitsky V.
    J Virol; 2007 Feb 01; 81(3):1390-400. PubMed ID: 17108039
    [Abstract] [Full Text] [Related]

  • 12. Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected b cells following capture of BHRF1 antigen.
    Landais E, Saulquin X, Bonneville M, Houssaint E.
    J Immunol; 2005 Dec 15; 175(12):7939-46. PubMed ID: 16339529
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
    Li D, Qian L, Chen C, Shi M, Yu M, Hu M, Song L, Shen B, Guo N.
    J Immunol; 2009 Feb 15; 182(4):1799-809. PubMed ID: 19201831
    [Abstract] [Full Text] [Related]

  • 14. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows SR.
    Eur J Immunol; 1995 May 15; 25(5):1374-84. PubMed ID: 7774641
    [Abstract] [Full Text] [Related]

  • 15. Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle.
    Williams LR, Quinn LL, Rowe M, Zuo J.
    J Virol; 2016 Jan 15; 90(2):947-58. PubMed ID: 26537677
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways.
    Zuo J, Quinn LL, Tamblyn J, Thomas WA, Feederle R, Delecluse HJ, Hislop AD, Rowe M.
    J Virol; 2011 Feb 15; 85(4):1604-14. PubMed ID: 21123379
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.
    Lee SP, Wallace LE, Mackett M, Arrand JR, Searle PF, Rowe M, Rickinson AB.
    Int Immunol; 1993 May 15; 5(5):451-60. PubMed ID: 8391306
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.